CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies

Forensic Science International

Volumn 158, Issue 2-3, 2006, Pages 177-183

  Koski, Anna ^a   Sistonen, Johanna ^a   Ojanperä, Ilkka ^a   Gergov, Merja ^a   Vuori, Erkki ^a   Sajantila, Antti ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Amitriptyline; CYP2C19 gene; CYP2D6 gene; Forensic; Pharmacogenetics; Toxicology

Indexed keywords

AMITRIPTYLINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DRUG METABOLITE;

ARTICLE; AUTOPSY; CADAVER; CORRELATION ANALYSIS; DRUG HYDROXYLATION; DRUG INTOXICATION; DRUG METABOLISM; ENZYME METABOLISM; ENZYME SUBSTRATE; GENE FUNCTION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MEDICOLEGAL ASPECT; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN METABOLISM; SUICIDE; TRANS ISOMER;

EID: 33645034693     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2005.05.032     Document Type: Article

References (31)

1. C. Barbui, and M. Hotopf Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials Br. J. Psychiatry 178 2001 129 144
2. U. Breyer-Pfaff, B. Pfandl, K. Nill, E. Nusser, C. Monney, M. Jonzier-Perey, D. Baettig, and P. Baumann Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes Clin. Pharmacol. Ther. 52 4 1992 350 358
3. O.V. Olesen, and K. Linnet Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes Pharmacology 55 5 1997 235 243
4. K. Venkatakrishnan, D.J. Greenblatt, L.L. von Moltke, J. Schmider, J.S. Harmatz, and R.I. Shader Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4 J. Clin. Pharmacol. 38 2 1998 112 121
5. K. Shimoda, T. Someya, A. Yokono, S. Morita, G. Hirokane, S. Takahashi, and M. Okawa The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients J. Clin. Psychopharmacol. 22 4 2002 371 378
6. B. Mellström, L. Bertilsson, J. Sawe, H.U. Schulz, and F. Sjöqvist E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation Clin. Pharmacol. Ther. 30 2 1981 189 193
7. J.L. Bock, E. Giller, S. Gray, and P. Jatlow Steady-state plasma concentrations of cis- and trans-10-OH amitriptyline metabolites Clin. Pharmacol. Ther. 31 5 1982 609 616
8. R.F. Suckow, and T.B. Cooper Simultaneous determination of amitriptyline, nortriptyline and their respective isomeric 10-hydroxy metabolites in plasma by liquid chromatography J. Chromatogr. 230 2 1982 391 400
9. E. Nusser, K. Nill, and U. Breyer-Pfaff Enantiomer analysis of E- and Z-10-hydroxyamitriptyline in human urine J. Chromatogr. 528 1 1990 163 171
10. K. Brøsen Some aspects of genetic polymorphism in the biotransformation of antidepressants Thérapie 59 1 2004 5 12
11. J. Kirchheiner, K. Nickchen, M. Bauer, M.L. Wong, J. Licinio, I. Roots, and J. Brockmoller Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Mol. Psychiatry 9 5 2004 442 473
12. W.H. Chou, F.X. Yan, J. de Leon, J. Barnhill, T. Rogers, M. Cronin, M. Pho, V. Xiao, T.B. Ryder, W.W. Liu, C.T. Teiling, and P.J. Wedlund Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness J. Clin. Psychopharmacol. 20 2 2000 246 251
13. T. Rau, G. Wohlleben, H. Wuttke, N. Thuerauf, J. Lunkenheimer, M. Lanczik, and T. Eschenhagen CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study Clin. Pharmacol. Ther. 75 5 2004 386 393
14. F.R. Sallee, C.L. DeVane, and R.E. Ferrell Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency J. Child. Adolesc. Psychopharmacol. 10 1 2000 27 34
15. H. Druid, P. Holmgren, B. Carlsson, and J. Ahlner Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results Forensic Sci. Int. 99 1 1999 25 34
16. P. Holmgren, B. Carlsson, A.L. Zackrisson, B. Lindblom, M.L. Dahl, M.G. Scordo, H. Druid, and J. Ahlner Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19 J. Anal. Toxicol. 28 2 2004 94 104
17. A.L. Zackrisson, P. Holmgren, A.B. Gladh, J. Ahlner, and B. Lindblom Fatal intoxication cases: cytochrome P(450)2D6 and 2C19 genotype distributions Eur. J. Clin. Pharmacol. 60 8 2004 547 552
18. P.J. Jannetto, S.H. Wong, S.B. Gock, E. Laleli-Sahin, B.C. Schur, and J.M. Jentzen Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases J. Anal. Toxicol. 26 7 2002 438 447
19. A. Levo, A. Koski, I. Ojanperä, E. Vuori, and A. Sajantila Postmortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood Forensic Sci. Int. 135 1 2003 9 15
20. S.H. Wong, M.A. Wagner, J.M. Jentzen, C. Schur, J. Bjerke, S.B. Gock, and C.C. Chang Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? J. Forensic. Sci. 48 6 2003 1406 1415
21. E. Lundqvist, I. Johansson, and M. Ingelman-Sundberg Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes Gene 226 2 1999 327 338
22. R. Løvlie, A.K. Daly, A. Molven, J.R. Idle, and V.M. Steen Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene FEBS Lett. 392 1996 30 34
23. V.M. Steen, O.A. Andreassen, A.K. Daly, T. Tefre, A.L. Borresen, J.R. Idle, and A.K. Gulbrandsen Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology Pharmacogenetics 5 4 1995 215 223
24. M. Oscarson, M. Ingelman-Sundberg, A.K. Daly, D.W. Nebert, Human Cytochrome P450 (CYP) Allele Nomenclature Committee, 2001 (http://www.imm.ki.se/ CYPalleles/ ).
25. J. Sistonen, S. Fuselli, A. Levo, A. Sajantila, CYP2D6 genotyping by a multiplex primer extension reaction. Clin. Chem. (2005), doi:10.1373/clinchem. 2004.046466.
26. I. Rasanen, I. Ojanperä, J. Vartiovaara, E. Vuori, and P. Sunila The advantage of dual-column approach and retention indices combined with refined reporting in gas chromatographic drug screening J. High Resolut. Chromatogr. 19 6 1996 313 321
27. D. Marez, M. Legrand, N. Sabbagh, J.M. Guidice, C. Spire, J.J. Lafitte, U.A. Meyer, and F. Broly Polymorphism of the P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution Pharmacogenetics 7 3 1997 193 202
28. C. Sachse, J. Brockmöller, S. Bauer, and I. Roots Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am. J. Hum. Genet. 60 2 1997 284 295
29. U.M. Zanger, S. Raimundo, and M. Eichelbaum Cytochrome P450 2D6: overview and update on pharmacology, genetics Naunyn Schmiedebergs Arch. Pharmacol. 369 1 2004 23 37
30. S. Rendic Summary of information on human CYP enzymes: human P450 metabolism data Drug Metab. Rev. 34 1-2 2002 83 448
31. W. Steimer, K. Zopf, S. von Amelunxen, H. Pfeiffer, J. Bachofer, J. Popp, B. Messner, W. Kissling, and S. Leucht Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers Clin. Chem. 50 9 2004 1623 1633